-

Agilent Included in Just Capital’s 2023 List of Most Just Companies

Ranking Underscores Agilent’s Strong Performance on Issues of Greatest Importance to Americans

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned the top ranking in its sector for industry-leading performance regarding treatment of employees, customers and the environment.

Just Capital and CNBC based the rankings on a review of the policies and practices of 1,000 of the largest U.S. public companies on issues that matter most to Americans, including wages and benefits, job creation, worker health and safety, ethical leadership, and environmental stewardship.

Agilent’s top ranking on worker issues reflects its commitment to being an employer of choice globally. In 2022, Agilent earned Great Place to Work® Certification in 20 countries and regions, including the United States, and was recently ranked among the best workplaces in health care by Fortune.

Just Capital also ranked Agilent number one in the industry for its treatment of customers. For the past two years, Agilent has ranked in the top five in customer satisfaction by the Wall Street Journal and the Drucker Institute’s annual list of the best-managed companies.

“Agilent employees work closely with our customers to bring great science to life and to carry out our mission to advance the quality of life,” said Neil Rees, Agilent’s head of Environmental, Social, and Governance (ESG) Programs. “Treating our employees well and creating products that help our customers improve human health and reduce environmental impact are essential to our ESG commitment.”

Agilent has reported on its corporate responsibility practices for over 20 years. The company is included in the JUST U.S. Large Cap Diversified (JULCD) Index and the Dow Jones Sustainability Indices (DJSI). Read more about Agilent’s commitment to net-zero emissions, diversity and inclusion, and other ESG initiatives.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Completes Acquisition of Biocare Medical

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st...

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...
Back to Newsroom